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Abstract
This paper presents a joint position of the UK-France Genomics and Ethics Network (UK-FR GENE), which has been set
up to reflect on the ethical and social issues arising from the integration of genomics into routine clinical care in the UK
and France. In 2018, the two countries announced enhanced cooperation between their national strategies, Genomics
England and Plan France Médecine Génomique 2025, which offers a unique opportunity to study the impact of genomic
medicine and relevant policies in different national contexts. The paper provides first insights into the two national
strategies and the norms, values and principles at stake in each country. It discusses the impact of genomic medicine on
established relationships and existing regulations, and examines its effects on solidarity and trust in public healthcare
systems. Finally, it uses the social contract as an analytical lens to explore and redefine the balance between individual
rights and collective duties in the context of genomic medicine. This paper leads to three key observations: (1) despite
each country’s strategy being at a different stage of implementation, the two countries face similar ethical issues; (2)
each country tries to solve these issues by (re-)defining individual rights and collective duties in its own way; (3) the
social contract presents a useful tool to analyse the ways the UK and France address the ethical challenges raised by
genomics. This overview lays the groundwork for future in-depth comparison, and drive collaborative research, between
the UK and France.
Introduction
In 2018, the UK and France announced enhanced coop-
eration between their national strategies, Genomics England
(GE) and Plan France Médecine Génomique 2025 (PFMG),
to develop genomic medicine [1], offering a unique
opportunity to study the ethical and social issues arising
from the integration of genomics into routine clinical care in
these countries. For this purpose, the two principal authors
of this paper initiated the UK-France Genomics and Ethics
Network (UK-FR GENE) in 2018, with the aim to bring
together researchers from each country to reflect on these
issues and develop a joint research agenda. The first UK-FR
GENE workshop was held in 2019. Amongst other things, it
demonstrated that an in-depth understanding of the impact
of genomic policies requires a thorough reflection on the
norms, values and principles that are at stake regarding
genomic medicine and its implementation.
This paper provides a first insight into some of these
norms, values and principles in each country and lays the
groundwork for future in-depth comparison between the
UK and France. We start with describing the two national
strategies and proceed to highlight the impact of and
changes brought about by the implementation of genomic
medicine regarding a variety of relationships (e.g.,
between patients and healthcare professionals) and reg-
ulations such as laws or professional guidelines (e.g., on
privacy and data protection) in each country. Finally, we
examine how the integration of genomics into routine care
raises questions about how to maintain the solidaristic
character [2] of, and public trust in, public healthcare
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systems. We conclude by reflecting on the usefulness of
the social contract as an analytical lens to explore and
redefine the balance between individual rights and col-
lective duties in the context of genomic medicine. Despite
the different stages of development of the two national
strategies, they nevertheless offer an important starting
point to compare the state of art, the regulations and
arguments that shape the implementation of genomic
medicine in each country.
Implementing genomics into clinical care:
two national strategies
GE and PFMGs’ aims are to integrate genomics into
routine healthcare in order to improve diagnosis for rare
disease and cancer and better target personalised treatment
options. In the UK, GE launched the 100,000 Genomes
Project (100 kGP) in 2012 with the aim of sequencing 100
k genomes from around 85,000 National Health Service
(NHS) patients with rare disease or cancer and this has
been delivered since 2014 through 13 NHS Genomic
Medicine Centres across England [3]. It is important to
mention that several genomes may be sequenced for each
patient (e.g., “trio testing” whereby the genomes of both
parents are sequenced alongside of a child’s in rare dis-
ease, and tumour as well as germline genomes are
sequenced in cancer). GE is a private company wholly
owned by the UK’s department of health and social care
offering participants a potential diagnosis as well as the
opportunity to take part in research (see below). Thus the
100 kGP has been presented as a ‘hybrid’ between
research and clinical care. When rolled out fully in spring
2021, the NHS Genomic Medicine Services will provide
access to genetic and genomic testing across England
through the public health sector.
In France, in order to drive the development of genomic
medicine, the PFMG aims to sequence 235,000 genomes
per year from 2020. Four pilot projects will be put in place
to improve diagnosis, prognosis and treatment for cancer,
rare diseases (e.g., intellectual disability syndromes) and
common diseases (e.g., diabetes), and to improve the
interpretation of genetic variants by indexing existing var-
iants in the French population. To reach this aim, a network
of 12 sequencing services will be gradually set up across the
country, of which only two are set up to date.
One of the main challenges regarding the implementation
of genomics in both countries concerns obtaining valid
consent in the context of complex and often uncertain
genomic information. The 100 kGP has adopted an open-
ended consent approach allowing participants, as diagnosis
evolves, to decide whether to receive secondary (clinically
actionable) findings or not; the list of possible secondary
findings are determined (but still not finalised) by the 100
kGP not the participants [4]. This approach has been
adapted from various recommendations on diagnostic inci-
dental or secondary findings such as the American College
of Medical Genetics and Genomics (ACMG). However, it
should be noted that GE is proposing to return information
about only a small subset of the genes included in the
ACMG list of those loci in which secondary findings will be
sought. In 2019, the Joint Committee on Genomics in
Medicine published guidelines for consent and con-
fidentiality in clinical practice [5]. The guidance highlighted
that the definition of a secondary finding as actionable was
too simplistic as ‘actionability’ is defined differently by
different groups, and variants have different degrees of
certainty as well as risk associated with them. Hence, the
guidance emphasises the importance of the clinical context
in communication of secondary findings as part of the NHS
Genomic Medicine Service. Furthermore, the guidance
emphasises the potential implications of genomic findings
for family members.
To date, France has not adopted a specific legal frame-
work regarding valid consent to genomic testing, and the
current Bioethics Law applies to genomic testing. The civil
code, in line with the Oviedo convention (1997, ratified by
France in 2011), primarily aims at protecting ‘the integrity
of the human species’ (ban on eugenics, article 16-4). In
addition, it states that genetic tests can only be undertaken
for research or medical purposes (article 16-10). Hence, in
the clinical context, consent can only be given for specific
conditions in symptomatic patients (e.g., for diagnosis or
the guidance of treatment) or asymptomatic patients (e.g. in
case of susceptibility or predisposition due to family his-
tory) [6]. However, in research, it is possible to return
incidental findings that indicate a serious genetic disease, if
the participant has given his/her explicit consent for this. In
2019, the PFMG has issued patient information sheets and
informed consent templates [7] for both research and
clinical care. The revision of the Bioethics Law (Title II,
Chapter 2, articles 17–18; Title IV, Chapter 2, articles
8 sq.), to be adopted in 2021, may introduce two major
changes regarding genetic and genomic testing. First, tests
could be allowed even if the person cannot express her will
or is dead, if the aim is prevention or improvement of care
for relatives. Second, health professionals could be allowed
to reveal incidental findings if the patient consents to it
prior to testing, including in the case of prenatal testing (in
this case, the above mentioned consent form templates will
be adapted accordingly). A list with additional findings to
search for, as proposed by the ACMG, is not envisaged.
The example of valid consent and the scope of testing in
the genomic context demonstrate how new technologies
initiate change and a rethinking of existing practices and
principles.
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The impact of genomic medicine on various
kinds of relationships
Blurred boundaries between research and clinical
care
The implementation of genomics in clinical care and
research impacts several relationships, including that
between research and clinical care. The need for a strict
division between research and clinical care was explicitly
stated in the Belmont Report (1969). However, the blurring
of these activities has been observed in many areas of
biomedicine [8], including the field of genomics [3, 9].
Consequently, the implementation of genomics in a (clin-
ical) research setting raises a number of ethical issues for
both researchers and clinicians, such as when should
sequencing activity be regarded as research or care [3], how
should clinically relevant findings generated during clinical
research sequencing be managed and who should be
responsible for their management [10]. A lack of clarity
about the nature of sequencing activities, whether they are
research or care, raises important questions regarding the
relationship between researchers (clinicians) and partici-
pants (patients), specifically, the extent to which they have a
duty to feedback clinically significant research findings to
these stakeholders and their family members, who may have
been involved in undergoing sequencing for research
purposes.
In the UK, attempts have been made to impose some
ethical boundaries on sequencing research in order to cir-
cumvent these ambiguities. For example, in GE’s 100 kGP,
access to whole-genome sequencing to aid their clinical
diagnosis/treatment, required patients to consent to their
DNA samples being used in research, and also gave them an
opportunity to consent to receiving a prescribed, limited list
of health-related additional findings. In France, at the time
of writing this paper, the issue of communicating additional
findings in research and clinical care remains unsettled [11].
Despite the questions raised by the blurred boundaries
between research and clinical care in genomics, it is
important to acknowledge that the shared aim of both,
research and care, is the improvement of health.
Changing relationships between patients and health
professionals
Genomics challenges not only the boundaries between
research and clinical care but also the relationship between
patients and healthcare professionals. Genomic tests, e.g.,
for diagnostic or predictive purposes, are complex processes
and rely on evolving sets of skills, which can challenge
healthcare professionals. Laboratory reports may not always
be definitive [12], and the interpretation of results not
always straightforward. It has been reported that profes-
sionals often are uncomfortable interpreting the clinical
significance of the results and communicating these to the
patients [13] not least because for some of the detected
conditions/genetic predispositions, treatment or prevention
may not be available, and patients may have overly opti-
mistic expectations of what genomic testing may reveal
[14]. In some cases, patients may have undergone a series of
unsuccessful examinations to obtain a diagnosis before they
are offered a genomic test, whereas others may have a
family history of a genetic condition. As genomics is
entering most areas of clinical medicine, more healthcare
professionals have to respond to new challenges and are
faced with complex genomic information, often with rather
limited training in, or exposure to, genomics.
In addition to these challenges and uncertainties, geno-
mic testing also raises questions about professional duties
such as the duty to recontact patients if understanding of the
implications of a detected variant changes since the time of
testing [15]. Furthermore, when a genomic test is per-
formed, there may be unexpected findings that are not only
relevant to the patient, but also to their broader family. In
such cases, clinicians may become aware of tensions in their
duty to care for their patient and respect his/her con-
fidentiality, and their duty to use this genomic information
in the care of his/her family [16].
The UK and France have addressed these issues by
balancing collective and family responsibilities against
individual rights in different ways. For over a decade,
French legislation has put a strong emphasis on the rights of
relatives to be informed about genetic tests results if they
are relevant to them. The law requires either and preferably
the patient, or the doctor (according to a specific procedure
protecting the confidentiality of the patient) to communicate
the relevant information to relatives (Law No. 2011-814,
2011). In England, such a duty has been established as a
duty to weigh the interests of relatives in the balance with
the interest of maintaining the confidentiality of one person
(a recent court ruling confirms this [2020] EWHC 455
(QB)). Often the interests of both patients and family
members can be respected without the need to decide in
favour of preservation or breach of confidence [17]. Gen-
erally, we observe an emphasis in both countries on con-
sidering the broader collective, familial or societal, aspect of
genomics.
Public involvement and the democratic sharing of
knowledge about genomic medicine
The increasing use of genomics in clinical care and the
complexity and challenges raised by the technologies to
assess genomics have led to concerns about public under-
standing and acceptance of genetics and genomics [18].
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There have been attempts to encourage a ‘peaceful’ debate
about these issues [19], by offering citizens the opportunity
to obtain information so that they may assess, and partici-
pate in, decisions about health policies and the allocation of
resources. However, while public engagement and lay
communication about genomic medicine are crucial for
broadening this debate, several problems have been iden-
tified with this, such as, the oversimplification of new sci-
entific insights, the difficulty of addressing the ‘real public’
[20] rather than specific groups, and the risk of adopting a
one-way communication model where experts educate the
lay public [21].
Both the British and French governments emphasise the
importance of public engagement in the context of geno-
mics. For example, the recent PFMG report addresses the
question of how to inform and involve civil society [22] and
has charged the National Institute for Health and Medical
Research (INSERM) with implementing this. Similarly,
Patient and Public involvement is an essential aspect of
GE’s strategy to implement genomic medicine. However,
one central issue regarding public engagement, in both
countries, is how engagement with publics, e.g. knowledge
sharing, is conceived beyond the application of the minimal,
and somehow rhetorical, principle of ‘you should at least
ask’ [23]. One aspect to take into account is that we are in
an era of epistemic transition [24]. Education about geno-
mics in life sciences programmes in schools, as already
happens in French high schools, could also improve public
understanding and involvement in the future.
Another issue is the involvement of members of the
public in research by co-opting one or two “public repre-
sentatives” as members of a project steering group. It is
currently unclear how effective such initiatives may be, in
terms of the extent to which these individuals can influence
the research process, as well as its ethical and legal framing.
In order to effectively involve the public, the only way to
proceed may be to adopt democratic procedures and tools,
however, ‘imperfect, slow, difficult and expensive’ they
may be [25]. As we will see in the next section, transitions
and changes in the genomic era not only occur at a rela-
tional level (e.g., between professionals and patients or
science and the public), but also at a regulatory level.
Changing regulations
The protection of personal data at European and
national levels
At the highest level, human rights law governs a person’s
private life, including data about them. For the purpose of
this article, we focus on data protection law at a European as
well as national level. The General Data Protection
Regulation 2016/679 (GDPR) came into force in 2018. It
regulates the processing of personal data across the Eur-
opean Union and European Economic Area. At the time of
writing, the GDPR still applies in the UK, despite its exit
from the EU. The GDPR promotes responsible data pro-
cessing for the benefit of the common good, while also
respecting individuals’ fundamental rights. While it is a
binding legislative act it also provides a wide margin of
manoeuvre for EU Member States, including for the pro-
cessing of ‘sensitive data’ such as genetic data [26].
In the UK, while there is no specific law governing the
processing of genetic data, the Data Protection Act 2018
gives effect to the GDPR. This stipulates that processing
‘special category data’ for scientific research is permitted
only if it does not cause harm to the data subject, is
approved by a research ethics committee, and is in the
public interest. In France, sensitive data have been protected
by the ‘Law on Data Processing, Data Files and Individual
Liberties’, since 1978 and by the French Bioethics Laws of
1994. Any processing of sensitive data in the public sector
must be authorised by the National Commission on Infor-
matics and Liberty (Law no 2018-493 of 20 June 2018).
Consequently, any processing of sensitive data requires
informed consent of the concerned person (or another valid
legal basis), prohibits any commercial use of this informa-
tion, and ensures the right to privacy (i.e., only the health
care professional in charge has access to genetic informa-
tion). Any violation of the processing of sensitive data is
sanctioned by the criminal code (articles 226-25–226-30).
Balancing privacy and data sharing
The term ‘privacy’ is not mentioned per se in the GDPR
(nor is the term ‘private life’). Data protection and privacy
are related but distinct concepts. Privacy, at least in its
informational dimension, is a state of affairs whereby data
relating to a person are in a state of non-access. It embo-
dies a broad range of rights and values, such as the right to
be left alone, intimacy, seclusion, and personhood. Data
protection is a set of legal rules protecting the rights,
freedoms, and interests of individuals whose personal data
are processed. The definitive objective of data protection is
to ensure fairness in the processing of data and, to some
extent, fairness in the outcomes of such processing. The
aims of data protection, then, are broader than simply
privacy protection, but at the same time, data protection is
a crucial tool to ensure privacy. The framing of privacy
protections in other EU texts and conventions mentioned
above present a political–philosophical approach that
should inform laws, be they on the EU level or the
member-state level. In addition, the inclusion of genetic
information within the category of sensitive data should be
noted [27].
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Whereas privacy (and data protection) are an expression
of our individual liberty, and hence constitute core values in
European society, they are not absolute and must be
balanced with other values such as the promotion of
(individual and public) health. As the GDPR and its
national adaptations demonstrate, it may be appropriate to
share genomic and health-related data that is potentially
(re-)identifiable with certain authorities and institutions.
In addition to this, the GDPR introduces a new ‘right to
data portability’ (article 20) enabling individuals to
receive their personal data, e.g., genomic data, which they
have provided to a controller (such as a research organi-
sation or hospital), in a ‘structured, commonly used and
machine-readable format’, and to transmit those data to
another data controller, e.g., for secondary or otherwise
further analyses. This raises important questions of how to
implement this right without creating or exacerbating data
security risks.
Since the launch of the Human Genome Project in
1990, genomic research has been a pioneering field in the
development of data sharing practices and policies.
Today, large funding bodies require the sharing of
sequence data to be considered in all funding applications
in genomics. The rationale for such a change is that data
produced by publicly funded bodies should be available
as soon and as widely as possible in the research com-
munity to enhance scientific endeavours and benefit the
public. However, data sharing in genomics as well as in
other scientific fields raises practical and ethical issues,
since sharing practices may complicate responsibilities
towards participants and make it difficult for data creators
and curators to be acknowledged within current systems
of scientific evaluations.
In the PFMG, data sharing practices are recognised in
principle. Their implementation and conformity with the
GDPR will be discussed as part of the next strategy phase,
when data will be produced. GE has already adopted a
‘reading library’ model, where the data are stored in the
National Genomic Research Library and is accessed by
researchers via a Trusted Research Environment. This is a
comprehensive resource allowing approved researchers to
securely access de-identified genomic and other asso-
ciated health data within the Library. Anyone accessing
the 100 K GP dataset—including GE staff, service pro-
viders, academic or commercial researchers—must apply
to an independent Access Review Committee to access
de-identified data and demonstrate the scientific con-
tribution of their research or its potential benefit to the
participants. The Committee is made up of senior inde-
pendent experts and an equal number of participants
drawn from the GE Participants Panel. The Committee
also monitors the progress of research and the opportu-
nities for rapid implementation of findings to benefit
patients. The limitation of privacy protection in the UK
and France only seems to be justified when these indivi-
dual rights are outbalanced by collective benefits and a
commitment to the common good.
Towards a new social contract
Trust and solidarity
Solidarity is the founding principle of publicly funded
healthcare systems, it occupies an important place in the
development of healthcare policies in Europe, and has
underpinned the social contract between healthcare systems
and members of society since the late 19th century. Soli-
daristic healthcare systems are based on ‘a feeling of
responsibility […] togetherness and commitment to the
common good’ [28] which provide the basis for public trust
[29]. Although the British and French public healthcare
systems are among the most trusted and respected public
institutions in these countries, funding cuts have led to a
decrease in trust in recent years [30, 31]. Some governments
seem to try to address the funding crisis in healthcare by
focusing on new health technologies, such as data-driven
sciences, that promise economic growth and on partnerships
with private companies [32].
The two initiatives, GE and PFMG, are examples of
national strategies that are centred on genomics, with the
aim of growing new industries, forging collaborations
between the public and private sector and demonstrating the
economic value of health data. However, profit-driven
collaborations have the potential to challenge the solidar-
istic character—i.e., the focus on the common good of
public actors (or, as is the case with GE, government
owned companies)—of these healthcare systems. This is
particularly important when these collaborations involve
patient data as it raises concerns regarding confidentiality
and privacy, but also trust among the public. For example,
in 2016, heavy criticism arose after the UK’s data protec-
tion watchdog ruled that a deal to share 1.6 million NHS
patient records with the Google-owned artificial intelli-
gence company DeepMind ‘failed to comply with data
protection law’. Patients had not been informed that the
company would be given access to their data. To address
the concerns and provide transparency, DeepMind pub-
lished all its contracts. Yet, in 2019, new concerns were
raised when a number of NHS trusts transferred these
contracts to Google Health, who refused to make the new
contracts transparent [33], failing to obtain public approval,
i.e., a ‘social licence’ [34].
Despite the difficulties raised by public–private part-
nerships, some healthcare systems, such as NHS England,
may decide to enter commercial partnerships to gain early
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access to technology or because they hope for financial
advantages. The question arises then as to whether it is
possible to build trustworthy public–private sector part-
nerships that preserve the solidaristic character of public
institutions and actors [35]. Arguably, if public healthcare
systems want to maintain their solidaristic character and
foster public trust, a solidarity grounded partnership model
with private companies may offer a solution. Such a model
needs to serve collective interests by, for example, secur-
ing preferential access to goods and services, providing
health benefits, and monitoring data access (e.g. GE’s
‘research library’ model).
What is the ‘value’ of genomics?
Trust in genomics not only concerns trust in institution,
but also trust in the ‘value’ of the technology, i.e., its
clinical utility, benefits, efficiency and quality, and in the
way it is set-up to be ‘valuable’, hence trustworthy. The
use of genomics in clinical care may lead to diagnoses and
treatments that are more detailed and focused on a single
patient, and which may result in improved health out-
comes. Commonly, when a new healthcare intervention is
integrated into clinical practice, careful cost-benefit ana-
lyses are undertaken to determine its ‘value’ i.e. to weigh
its health benefits against the costs [36]. The criteria used
to determine this value vary between countries. Alter-
natively, value can be determined by asking people
directly about their health preferences and perceived
benefits of a new intervention, using discrete choice
experiments (DCE) [37]. Genomic tests are currently
entering clinical practice in the UK and France without
this evidence and little data on the health economic value
of genomics exist in the literature. A recent systematic
review reported that the current evidence base on the cost-
effectiveness of genome sequencing is insufficient to
support widespread use of these tests in clinical practice
[38]. In addition, the amount of money patients and/or
healthcare professionals would be willing to spend on
genomic tests, and the general benefits attributed to these,
varies widely, according to the DCE literature [39].
Finally, although it is often stated that genomic data
provides wider benefits for national economies [40], no
studies have evaluated this broader economic value
to date.
Another aspect to be considered in the determination of
the ‘value’ of genomics is data quality. In order to fulfil the
promises made by genomics, data must meet strict quality,
standardisation and ethical requirements. These require-
ments ensure comparability and exchange of data to support
collaborations, transparency and reproducibility and ulti-
mately scientific advances [41].
In order to promote public trust and support of geno-
mics, the ‘value’ of genomic data for science, public
health and the economy must be carefully examined, and
thorough studies are needed to ensure that resources are
allocated efficiently and to the benefit of the
common good.
The social contract in the light of genomic
technologies
Genomics challenges broadly accepted individual-focused
principles (e.g., valid consent or privacy) and requires these to
be redefined in the light of, and balanced with, collective
values and benefits. Against this background, bioethicists and
policy-makers have begun to discuss the need to rethink the
‘social contract’ between medicine/science and society, away
from exclusively individual-focused solutions [42, 43]. The
concept of a social contract has been developed by political
philosophers (e.g., Locke, Rousseau or Rawls) to describe a
set of formal and informal norms and rules that lay out
expectations of the rights and duties of citizens [44].
In England, a country with an individualistic tradition,
yet also a solidaristic healthcare system, public institutions
and documents suggest there is a need for a ‘new social
contract for genomic medicine’, and greater focus on the
collective dimensions of genomics i.e. the importance of
community participation, public interest and trust [43, 45, 46].
For example, GE has called upon the public’s civic duty to
participate in the 100 kGP as a contribution to the common
good and an expression of solidarity [47]. Yet, since the value
of genomics, and hence its contribution to the common good,
has not yet clearly been defined, the question arises as to
whether the call for solidarity is merely rhetorical.
However, beyond the mobilisation of the idea of the
social contract at a policy level, the social contract can
provide a useful lens to analyse, at a theoretical level, the
ethical challenges raised by genomics. These challenges
arise because genomics questions the appropriateness of
well-established individual-focused principles of 20th cen-
tury bioethics such as valid consent, confidentiality or
privacy, which have come to shape the doctor–patient
relationship, practices and public trust in medicine in many
Western countries [48]. Employing the social contract as an
analytical lens allows us to explore how each society
responds to the challenges posed by genomics, i.e. how it
(re-)defines and balances collective and individual rights
and duties, and values associated with these.
Presently, the UK follows an approach that prioritises the
interests of the individual, and respect for confidentiality and
privacy is paramount, as demonstrated by the ‘research
library’ model adopted by GE and the legal disputes about the
recognition of the rights of the family with regard to genomic
information. On the contrary, in France, even though policy
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debates and legal regulations of genomics also focus on
individual rights [49], high value is placed on familial inter-
ests that go beyond those of the individual such as is the case
with regard to familial access to genomic information. These
are just some indications of how each country has begun to
negotiate and redefine collective and individual responsi-
bilities and rights in the context of genomics.
Conclusions
This paper provides an overview of some of the ethical
issues raised by the UK and French national strategies to
establish genomic medicine as part of routine healthcare.
This overview is part of a broader research ambition to offer
in-depth understanding of the impact of genomic medicine
and relevant policies in these two countries.
Our paper leads to three key observations: First, it
emerges that the two countries face similar ethical issues
(e.g., blurred boundaries between research and clinical
care, securing valid consent in the context of complex and
uncertain information), even though their national strate-
gies are not at the same stage of implementation. A second
observation is that each country tries to solve these issues
by balancing individual and collective interests differ-
ently. For example, the limitation of privacy rights is
justified in both countries only if this serves the common
good. The GDPR is an example of this and shows how
regulations (e.g., laws or professional guidelines) express
commonly accepted values and frame professional, indi-
vidual and public decisions. Our third observation is that
the concept of the social contract presents a useful tool to
analyse the ways the UK and France address the ethical
challenges raised by genomics. As highlighted, the col-
lective aspects of genomic information question the
appropriateness of individual-focused ethical principles
(e.g. valid consent, confidentiality or privacy) that have
been established in response to advances in medicine and
changing social attitudes in the 20th century. This raises
similar ethical issues across countries that promote indi-
vidual rights and liberties, such as the UK and France, and
requires each country, in its own way, to redefine indi-
vidual rights and collective duties.
These three observations are relevant for further analysis
of the ethical issues, yet they do not lead to the conclusion
that the UK and France address these issues similarly. Our
discussion identifies significant differences between the two
countries, especially with regard to individual versus family
rights, approaches adopted towards consent or public
engagement models, and the role of private companies in
the public healthcare system. These and other aspects
should be further investigated. The aim of UK-FR GENE is
to drive collaborative research and a series of workshops to
generate an in-depth understanding of similarities and dif-
ferences in the ways each country addresses the ethical
issues identified.
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